Con esta herramienta te facilitamos un acceso a todas las ofertas y demandas de tecnología europeas y a búsquedas de socios para participar en propuestas europeas de I+D publicadas en la red Enterprise Europe Network, pudiendo filtrar los resultados para facilitar las búsquedas más acordes con tus necesidades.

¿Quieres recibir estos listados de oportunidades de colaboración en tu correo de forma periódica y personalizada? Date de alta en nuestro Boletín

Para optimizar los resultados de la búsqueda, se recomienda utilizar términos en inglés.

Método no invasivo para determinar el factor Rh y género del feto con sangre materna desde la décima semana de embarazo

Resumen

Tipo:
Oferta Tecnológica
Referencia:
TORU20151118001
Publicado:
26/11/2015
Caducidad:
26/11/2016
Resumen:
Una empresa rusa desarrolla y fabrica kits de pruebas moleculares-genéticas (reacción en cadena de la polimerasa en tiempo real). La empresa ha desarrollado kits de reactivos para ácido desoxirribonucleico fetal con el fin de conocer el género y factor Rh del feto desde la décima semana de embarazo. El material con el que se investiga es una pequeña cantidad de sangre de la mujer embarazada, siendo una prueba totalmente segura para ella. La empresa busca laboratorios médicos públicos y privados y centros perinatales con el fin de establecer acuerdos comerciales con asistencia técnica. El objetivo es introducir la tecnología en instituciones médicas extranjeras.

Details

Tittle:
Noninvasive determination of fetal Rh factor and gender by maternal blood starting from 10 weeks of pregnancy.
Summary:
A Russian company from Ulyanovsk develops and manufactures molecular-genetic test kit (the technology of real-time polymerase chain reaction). It was developed reagent kits for fetal deoxyribonucleic acid, through which you can know the gender and Rh factor of the fetus at 10 weeks of pregnancy. The company is interested in signing commercial agreement with technical assistance.
Description:
Today 15% of pregnant have Rh-negative, so 50% of cases, they may be developed Rh factor incompatibility - one of the most frequent causes of hemolytic disease of the fetus and newborn. Hemolytic disease of the fetus and newborn - the most frequent cause of fetal death or infant mortality.
To promptly take measures to prevent rhesus incompatibility, it is necessary to know the Rh factor of the fetus, and this requires an invasive procedure (puncture through the abdomen of the pregnant woman). This procedure is dangerous: infection, solution of continuity of membranes, fetus wastage.
To solve this problem the Russian company from Ulyanovsk, which leads developments in the field of molecular genetic diagnostics, has developed a method to determinate the Rh factor of the fetus by maternal blood starting from 10 weeks of pregnancy.
The relevance of this method is confirmed by the fact that it is the reagent kits for the laboratory. The research material is a small amount of venous blood of a pregnant. It is absolutely safe for the expectant mother.
The use of results in obstetric-gynecologic practice will allow the specialist to take timely measures to prevent the Rh incompatibility. And it will help patients out of risk groups to avoid unnecessary researches and unnecessary anxiety.
Detection of deoxyribonucleic acid gene of the Rh factor by real-time polymerase chain reaction includes 3 stages:
- the isolation of deoxyribonucleic acid from blood of a Rh-negative pregnant;
- real-time polymerase chain reaction - amplification of deoxyribonucleic acid with simultaneous hybridization-fluorescent detection, which is produced during the passage of real-time polymerase chain reaction;
- interpretation of results;
- accumulation of 99%.
The company is interested in cooperation with public and private medical laboratories, perinatal centers under commercial agreement with technical assistance. Under the agreement, the company is ready to implement and introduce this technology in medical institutions abroad.
Advantages and Innovations:
The innovative aspect: the tests to determine Rh factor and the gender of the fetus are noninvasive method, namely by venous blood of a pregnant.
The accuracy of the test is 99%.
The test can be performed from 10 weeks of pregnancy.
The test results are known in a short time.
The tests are absolutely safe.
The development is a simple to use, it can be applied in any laboratory in the world equipped with real-time polymerase chain reaction equipment.
Stage of Development:
Already on the market
IPs:
Patents granted
CommeR Statunts Regarding IPR Status:
Russia, 2014

Partner sought

Type and Role of Partner Sought:
Field of work: medicine -Y- healthcare.
The type of potential partners: medical laboratory, perinatal centers, private medical centers.
Role: introduction and implementation of the technology in medical institution abroad.

Client

Type and Size of Client:
Industry SME 11-49
Already Engaged in Trans-National Cooperation:
Si
Languages Spoken:
English

Keywords

Technology Keywords:
06001005 Diagnósticos, diagnosis